Phase 1/2 × Leukemia × Cyclophosphamide × Clear all
NCT05589896 2026-02-24

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

Ossium Health, Inc.

Phase 1/2 Recruiting
12 enrolled
NCT00625729 2017-12-28

Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

Masonic Cancer Center, University of Minnesota

Phase 1/2 Terminated
6 enrolled 10 charts
NCT00809276 2015-02-16

Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Completed
92 enrolled 5 charts
NCT00003425 2013-04-26

Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect

University of Kentucky

Phase 1/2 Completed
25 enrolled
NCT00049634 2010-09-16

Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Disorder

Fred Hutchinson Cancer Center

Phase 1/2 Completed
30 enrolled
NCT00054340 2010-05-14

Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder

Fred Hutchinson Cancer Center

Phase 1/2 Completed